Zevra Therapeutics
As of the edition of 20 October 2026, Zevra Therapeutics runs 4 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Acer Therapeutics Inc.: acquired in 2023; successor Zevra Therapeutics
- Opexa Therapeutics, Inc.: acquired in 2023; successor Zevra Therapeutics
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Phenylbutanoic acid | none listed | 0 |
| Serdexmethylphenidate | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Mental health: 2 trials led
- Blood and lymph: 1 trials led
- Heart and blood vessels: 1 trials led